Tracking Gilead's 4 Big Stories and a Lawsuit in 2022

In this clip from "The Pharma & Biotech Show" on Motley Fool Live, recorded on Feb. 2, Motley Fool contributors Brian Orelli and Keith Speights discuss the major lawsuit between Gilead (NASDAQ: GILD) and [GlaxoSmithKline (LSE: GSK) majority-owned] ViiV Healthcare and analyze what effects the resulting settlement might have on future profits.

Brian Orelli: I think four things to watch in 2022 is Trodelvy, which has four Phase III clinical trials happening, three in breast cancer and one in lung cancer. That has the potential to grow sales of Trodelvy quite a bit. They have another Phase III for Magrolimab that's not on the market yet, but they're looking to get it into acute myeloid leukemia if that Phase III clinical trial is successful. Then, on the CAR T-cell therapy side, Yescarta, they're looking for U.S. approval for large B-cell lymphoma. That would expand sales in the United States. Then, they are looking to get an approval in the EU for follicular lymphoma in the first half, and then, Large B-cell lymphoma in the second half of the year. That has the potential to expand just CAR T sales substantially. Gilead, I think this quarter, just exemplifies what's been happening for the last couple of years. It just seems like it's just a wait-and-see kind of company.

Source Fool.com